Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
February 26, 2009

Tocris to Market Two AstraZeneca Compounds as Preclinical Cancer Research Tools

  • Tocris Bioscience obtained exclusive rights from AstraZeneca to supply two anticancer agents, anastrozole and bicalutamide, as preclinical research compounds.  Anastrozole is an aromatase inhibitor, and bicalutamide is an androgen inhibitor.

    “By making the fully licensed products available through our catalogue, we hope to promote new and exciting research in the fundamental processes that drive cancer development,” says Duncan Crawford, Tocris’ CSO.

Related content

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.